Literature DB >> 17047518

Absence of peroxisome proliferators-activated receptors (PPAR)alpha enhanced the multiple organ failure induced by zymosan.

Rosanna Di Paola1, Emanuela Esposito, Emanuela Mazzon, Tiziana Genovese, Carmelo Muià, Concetta Crisafulli, Giuseppe Malleo, Edoardo Sessa, Rosaria Meli, Salvatore Cuzzocrea.   

Abstract

The peroxisome proliferator-activated receptor (PPAR) alpha is a member of the nuclear receptor superfamily of ligand-dependent transcription factors related to retinoid, steroid, and thyroid hormone receptors. The aim of the present study is to evaluate the role of PPAR-alpha receptor on the development of multiple-organ dysfunction syndrome (MODS) induced by zymosan. MODS was induced by peritoneal injection of zymosan (dose, 500 mg/kg i.p. as a suspension in saline) in PPAR-alpha wild-type (PPAR-alphaWT) and PPAR-alpha knockout (PPAR-alphaKO) mice, was assessed 18 h after the administration of zymosan, and was monitored for 12 days (for loss of body weight and mortality). A severe inflammatory process, induced by zymosan administration in wild-type mice, coincided with the damage of liver, kidney, pancreas, and small intestine. Myeloperoxidase activity, indicative of neutrophil infiltration, and lipid peroxidation were significantly increased in zymosan-treated wild-type mice. Zymosan in the wild-type mice also induced a significant increase in the plasma levels of nitrite/nitrate. Immunohistochemical examination demonstrated a marked increase in the immunoreactivity to nitrotyrosine and Fas ligand in the intestine of zymosan-treated wild-type mice. In contrast, the degree of (1) peritoneal inflammation and tissue injury, (2) nitrotyrosine formation and Fas ligand expression, and (3) neutrophil infiltration were markedly enhanced in intestinal tissue obtained from zymosan-treated PPAR-alphaKO mice. Zymosan-treated PPAR-alphaKO mice also showed a significantly increased mortality. Taken together, the present study clearly demonstrates that PPAR-alpha pathway modulates the degree of MODS associated with zymosan-induced nonseptic shock.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17047518     DOI: 10.1097/01.shk.0000230299.78515.2c

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  13 in total

1.  Lack of PPARα exacerbates lipopolysaccharide-induced liver toxicity through STAT1 inflammatory signaling and increased oxidative/nitrosative stress.

Authors:  Seong Ho Yoo; Ogyi Park; Lauren E Henderson; Mohamed A Abdelmegeed; Kwan-Hoon Moon; Byoung-Joon Song
Journal:  Toxicol Lett       Date:  2011-01-22       Impact factor: 4.372

2.  Reduced peroxisome proliferator-activated receptor α expression is associated with decreased survival and increased tissue bacterial load in sepsis.

Authors:  Stephen W Standage; Charles C Caldwell; Basilia Zingarelli; Hector R Wong
Journal:  Shock       Date:  2012-02       Impact factor: 3.454

3.  Peroxisome proliferator-activated receptor alpha mediates C/EBP homologous protein to protect mice from acute liver failure.

Authors:  Xiangying Zhang; Peiling Dong; Hongbo Shi; Huaying Sun; Jianhui Lin; Dexi Chen; Zhongping Duan; Xiuhui Li; Feng Ren
Journal:  Inflamm Res       Date:  2017-06-09       Impact factor: 4.575

4.  PPARα mediates the anti-inflammatory effect of simvastatin in an experimental model of zymosan-induced multiple organ failure.

Authors:  Barbara Rinaldi; Maria Donniacuo; Emanuela Esposito; Annalisa Capuano; Loredana Sodano; Emanuela Mazzon; Donatella Di Palma; Irene Paterniti; Salvatore Cuzzocrea; Francesco Rossi
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

5.  Role of PPAR-delta in the development of zymosan-induced multiple organ failure: an experiment mice study.

Authors:  Maria Galuppo; Rosanna Di Paola; Emanuela Mazzon; Tiziana Genovese; Concetta Crisafulli; Irene Paterniti; Elisabetta Cuzzocrea; Placido Bramanti; Amar Kapoor; Christoph Thiemermann; Salvatore Cuzzocrea
Journal:  J Inflamm (Lond)       Date:  2010-02-18       Impact factor: 4.981

6.  Protection by mTOR Inhibition on Zymosan-Induced Systemic Inflammatory Response and Oxidative/Nitrosative Stress: Contribution of mTOR/MEK1/ERK1/2/IKKβ/IκB-α/NF-κB Signalling Pathway.

Authors:  Seyhan Sahan-Firat; Meryem Temiz-Resitoglu; Demet Sinem Guden; Sefika Pinar Kucukkavruk; Bahar Tunctan; Ayse Nihal Sari; Zumrut Kocak; Kafait U Malik
Journal:  Inflammation       Date:  2018-02       Impact factor: 4.092

7.  PPAR-gamma agonist protects against intestinal injury during necrotizing enterocolitis.

Authors:  Naira Baregamian; Joshua M Mourot; Amie R Ballard; B Mark Evers; Dai H Chung
Journal:  Biochem Biophys Res Commun       Date:  2008-12-27       Impact factor: 3.575

8.  Peroxisome proliferator-activated receptors in HCV-related infection.

Authors:  Sébastien Dharancy; Maud Lemoine; Philippe Mathurin; Lawrence Serfaty; Laurent Dubuquoy
Journal:  PPAR Res       Date:  2009-03-30       Impact factor: 4.964

9.  Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP.

Authors:  Jonas Bystrom; Ian Evans; Justine Newson; Melanie Stables; Iqbal Toor; Nico van Rooijen; Mark Crawford; Paul Colville-Nash; Stuart Farrow; Derek W Gilroy
Journal:  Blood       Date:  2008-09-08       Impact factor: 22.113

10.  Peroxisome proliferator-activated receptor α activation attenuates the inflammatory response to protect the liver from acute failure by promoting the autophagy pathway.

Authors:  M Jiao; F Ren; L Zhou; X Zhang; L Zhang; T Wen; L Wei; X Wang; H Shi; L Bai; X Zhang; S Zheng; J Zhang; Y Chen; Y Han; C Zhao; Z Duan
Journal:  Cell Death Dis       Date:  2014-08-28       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.